SuHyuk Chi, Jeong-Kyung Ko, June Kang, Jeong-An Gim, Moon-Soo Lee
{"title":"Longitudinal Analysis of Cytokine Profiles and Their Impact on Tic Disorder Severity Over One Year.","authors":"SuHyuk Chi, Jeong-Kyung Ko, June Kang, Jeong-An Gim, Moon-Soo Lee","doi":"10.9758/cpn.24.1266","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aims to explore the relationship between symptom severity and cytokine levels in patients with tic disorders by evaluating these parameters at baseline and after a one-year follow-up.</p><p><strong>Methods: </strong>A total of 44 tic disorder patients were recruited, 35 completed baseline assessments, and 20 completed endpoint assessments after one year. Based on changes in Yale Global Tic Severity Scale scores, patients were categorized into 'improved' and 'persistent' groups. Cytokine levels were measured using a Luminex<sup>Ⓡ</sup> human cytokine multiplex assay at both time points.</p><p><strong>Results: </strong>Significant increases were found in interferon (IFN)-α2, IFN-γ, interleukin (IL)-1β, IL-6, IL-10, IL-12 p40, IL-12 p70, and IL-13, while IL-1ra and IL-4 levels decreased. Changes in IFN-γ levels showed significant correlations with tic severity, with higher endpoint levels being linked to symptom worsening. Baseline IL-5 levels were significantly higher in the improved group compared to the persistent group.</p><p><strong>Conclusion: </strong>This study underscores the potential of IFN-γ and IL-5 as biomarkers and therapeutic targets in tic disorders. The findings suggest that these cytokines could be instrumental in assessing tic disorder severity and developing targeted therapies. Further research involving larger cohorts is needed to validate these findings and explore cytokine-targeted therapies for tic disorders.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"23 3","pages":"411-417"},"PeriodicalIF":2.4000,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12264676/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Psychopharmacology and Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.9758/cpn.24.1266","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study aims to explore the relationship between symptom severity and cytokine levels in patients with tic disorders by evaluating these parameters at baseline and after a one-year follow-up.
Methods: A total of 44 tic disorder patients were recruited, 35 completed baseline assessments, and 20 completed endpoint assessments after one year. Based on changes in Yale Global Tic Severity Scale scores, patients were categorized into 'improved' and 'persistent' groups. Cytokine levels were measured using a LuminexⓇ human cytokine multiplex assay at both time points.
Results: Significant increases were found in interferon (IFN)-α2, IFN-γ, interleukin (IL)-1β, IL-6, IL-10, IL-12 p40, IL-12 p70, and IL-13, while IL-1ra and IL-4 levels decreased. Changes in IFN-γ levels showed significant correlations with tic severity, with higher endpoint levels being linked to symptom worsening. Baseline IL-5 levels were significantly higher in the improved group compared to the persistent group.
Conclusion: This study underscores the potential of IFN-γ and IL-5 as biomarkers and therapeutic targets in tic disorders. The findings suggest that these cytokines could be instrumental in assessing tic disorder severity and developing targeted therapies. Further research involving larger cohorts is needed to validate these findings and explore cytokine-targeted therapies for tic disorders.
期刊介绍:
Clinical Psychopharmacology and Neuroscience (Clin Psychopharmacol Neurosci) launched in 2003, is the official journal of The Korean College of Neuropsychopharmacology (KCNP), and the associate journal for Asian College of Neuropsychopharmacology (AsCNP). This journal aims to publish evidence-based, scientifically written articles related to clinical and preclinical studies in the field of psychopharmacology and neuroscience. This journal intends to foster and encourage communications between psychiatrist, neuroscientist and all related experts in Asia as well as worldwide. It is published four times a year at the last day of February, May, August, and November.